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Report on NASA Project: Structure and Function of Non-Collagenous Bone Proteins
1. Description of Research
The long-term goal for this program is to determine the structural and functional relationships of
bone proteins and proteins that interact with bone. This information will used to design useful
pharmacological compounds that will have a beneficial effect fn osteoporotic patients and in the
osteoporotic-like effects experienced on long duration space missions. The first phase of this
program, funded under a cooperative research agreement with NASA through the Texas Medical
Center, aimed to develop powerful recombinant expression systems and purification methods for
production of large amounts of target proteins. Proteins expressed in sufficientamount and purity
would be characterized by a variety of structural methods, and made available for crystallization
studies. In order to increase the likelihood of crystallization and subsequent high resolution
solution of structures, we undertook to develop expression of normal and mutant forms of
proteins by bacterial and mammalian cells. In addition to the main goals of this program, we
would also be able to provide reagents for other related studies, including development of anti-
fibrotic and anti-metastatic therapeutics.
2. Research Achievements and Outcomes
Over the course of the current program we have set in place all the technologies required for the
high level expression, purification, and characterization of the complex proteins and glycoproteins
that comprise the mineralized matrix of mineralized tissues. Specifically, we have focused
attention on a complex glycoconjugate termed decorin, which has been expressed using different
systems (1, 2, 9), depending on particular requirements. Decorin represents a prototype for our
approach to study a broad range of bone proteins, and our success is encouraging. Briefly
decorin has been expressed in large quantity (>30 mg per batch) by use of recombinant vaccinia
viridae as both a proteoglycan and core protein form; however, the core protein is variably
substituted with 2-3 N-linked oligosaccharides. We have generated site-specific mutations in the
core protein so that carbohydrate attachment sites have been deleted; in addition, expression of
chemical amounts of homogeneous core protein by CHO mutant cell lines has increased the
spectrum of molecules produced and therefore increased the likelihood of crystallization. Decorin
and the related biglycan possess extensive secondary structure (8), and this project represents the
first time that these molecules have been produced in significant amount with maintenance of
putative functional domains. Other structural and functional studies have identified new activities,
including a zinc binding motif (9), and ability to modulate tumor cell growth by interaction with
cell surface receptors (6, 7). These studies have formed the basis of two new programs submitted
to the NIH for funding in the next cycle (see below). It is anticipated that similar approaches to
the other bone proteins will yield significant new information. The versatility of the mammalian
expression system has been greatly expanded (3, 5) by the development of a panel of expression
constructs that have been made available to several investigators. Recombinant vaccinia viridae
encoding other bone proteins have been generated and are now ready for large scale production.
In collaboration with the Center for Macromolecular Crystallography at the University of
Alabama at Birmingham, we are analyzing the structure of several bone protein-binding bacterial
proteins. Four of these proteins have been crystallized and the structure of a collagen binding
protein from S. aureus has been solved at a resolution of 1.9_ (4).
Publication_:
1. Hocking, A.M., Strugnell, R.A., Ramamurthy, P., and McQuillan, D.J. (1996) Eukaryotic
Expression of Recombinant Biglycan: post-translational processing, and the importance of
secondary structure for biological activity. J.Biol. Chem. 271, 19571-19577
2. Ramamurthy, P., Hocking, A.M., and McQuillan, D.J. (1996) Recombinant Decorin
Glycoforms: purification and structure. J. Biol. Chem. 271, 19578-19584
3. Chan, D., Weng, Y.M., Hocking, A.M., Golub, S., McQuillan, D.J., and Bateman, J.F.
(1996) Site-directed Mutagenesis of Human Type X Collagen: expression of t_l(X) NC1,
NC2 andhelical domainmutationsin vitro and in transfected cells. J. Biol. Chem. 271,
13566-13572
4. Symersky, J., Patti, J.M., Carson, M., House-Pompeo, K., Teale, M., Moore, D., Jin, L.,
Schneider, A., De Lucas, L.J., Hook, M., Narayana, S.V.L. (1997) Structure of the
collagen-binding domain from a Staphylococcus aureus adhesin. Nature Struct. Biol. 4,
833-838
5. Chan, D., Lamande, S.R., McQuillan, D.J., and Batemari, J.F. (in press) In vitro
expression analysis of collagen biosynthesis and assembly. Biochem. Biophys. Meth.
6. Moscatello, D.K., Santra, M., Mann, D.M., McQuillan, D.J., Wong, A.J., and Iozzo, R.V.
(in press ) Decorin supresses tumor cell growth by activating the epidermal growth factor
receptor. J. Clin. Invest.
7. Patel, S., Santra, M., McQuillan, D.J., Iozzo, R.V., and Thomas, A.P. (in press) Decorin
activates the EGF receptor and elevates cytosolic Ca 2÷ in A431 carcinoma cells. J. Biol.
Chem.
8. Krishnan, P., Hocking, A.M., Scholtz, M., Pace, C.N., and McQuillan, D.J. (submitted)
Comparative structural analysis of biglycan and decorin.
9. Yang, W-C., LaBrenz, S.R., Rosenberg, L.C., H66k, M. (submitted) Decorin: a zinc
binding protein
Grants submitted:
1. McQuillan, D.J. (P.I.) Biosynthesis, structure, and function of decorin. Submitted to the
NIH, RO1GM58009
2. Border, W.A., Noble, N.A., McQuillan, D.J. (co-P.I.s) Decorin: mechanisms of anti-
fibrotic effects. Submitted to the NIH (assignment number pending)
3. Future Goals
In the event that continued funding is available, we would anticipate pursuing second stage
objectives with proteins already produced in large amounts i.e. crystallization trials with decorin,
biglycan, cell surface integrin receptors, and COMP. We have in place expression constructs for
most of the other major bone proteins, and would proceed with large scale expression,
purification, and characterization prior to crystallization trials. It would be anticipated that in the
next two years we would have available high resolution structures for a number of bone proteins
and related structures. This would then set the stage for defining in detail the interactions in the
matrix, the role in mineral deposition and mineral loss, and initiate a rational drug design strategy
to treat disorders related to bone composition.
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Dear Ms. Schiflett:
Enclosed please find two manuscripts entitled, "Distinct Secondary Structures of the Leucine-
Rich Repeat Proteoglycans Decorin and Biglycan: glycosylation-dependent conformation
Zn 2+ metall0protein" respectively. These manuscripts presentstability" and "Decorin is a ,
studies partially supported by the NASA/JSC Cooperative Program as indicated in the
acknowledgements. The manuscripts have been submitted to the Journal of Biological
Chemistry. Before we proceed with the publication process, we request approval from
NASA/Johnson Space Center.
Sincerely yours,
Magn0.,qH66k, Ph.D.
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